Pfizer Inc. experienced lower-than-expected sales for its Covid pill and other key products in the second quarter, leading the company to revise its full-year sales forecast downwards by $1 billion. This disappointing performance raises concerns about Pfizer's ability to achieve its projected combined sales of $21.5 billion from its Covid products for the year.
During the peak of the pandemic, Pfizer's Covid shot and pill generated billions of dollars in revenue as global demand for vaccines and treatments soared. However, as the demand wanes and the company transitions to a model where health insurers, rather than governments, pay for these products, sales have significantly declined.
In the second quarter, Pfizer recorded total revenue of $12.7 billion, representing a 54% decrease compared to the same period last year. This decline was largely attributed to diminishing Covid demand. Furthermore, some of Pfizer's other top-selling products, such as the blood-thinner Eliquis and the pneumococcal vaccine Prevnar, also fell short of analysts' expectations during the quarter.
Comirnaty, Pfizer's Covid vaccine, reported sales of $1.49 billion in the second quarter, an 83% decrease from the previous year. Despite meeting analysts' estimates, the significant decline is a cause for concern. The quarterly sales of Paxlovid, the company's antiviral pill for Covid, were $143 million, which is a staggering 98% decrease compared to the previous year and fell far below Wall Street's expectations.
Pfizer's stock has suffered a significant decline over the past year, surpassing that of its industry rivals. Although the stock's downward trajectory is not expected to worsen significantly, analysts predict that its recovery may be challenging. The uncertainty surrounding Pfizer's Covid franchise, coupled with recent setbacks for the company's once-daily oral weight loss product, pose additional challenges for the company.
Despite the disappointing sales and revised forecast, Pfizer maintained its adjusted earnings guidance for the year, projecting earnings in the range of $3.25 to $3.45 per share. However, the company revised its revenue estimate to be as high as $70 billion, down from the previous forecast that peaked at $71 billion.
Analysts remain cautious about Pfizer's ability to achieve its full-year Covid sales target, and the questions surrounding its Covid franchise continue to linger. The company will need to address these concerns and overcome the challenges it faces to regain investor confidence and optimize its financial performance.